Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution

American Journal of Hematology

Volumn 89, Issue 8, 2014, Pages 813-818

  Tang, Guilin ^a   Zhang, Liping ^a   Fu, Bin ^a   Hu, Jianhua ^a   Lu, Xinyan ^a   Hu, Shimin ^a   Patel, Ankita ^b   Goswami, Maitrayee ^a   Khoury, Joseph D ^a   Garcia Manero, Guillermo ^a   Medeiros, L Jeffrey ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic myelomonocytic leukemia (CMML); Complex karyotype; Cytogenetics risk classification; Overall survival; Trisomy 8

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; LEUKEMIA FREE SURVIVAL; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TRISOMY 8;

CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML); COMPLEX KARYOTYPE; CYTOGENETICS RISK CLASSIFICATION; OVERALL SURVIVAL; TRISOMY 8;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; RISK; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRISOMY;

EID: 84904406511     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23751     Document Type: Article

References (23)

1. Worsley A, Oscier DG, Stevens J, et al. Prognostic features of chronic myelomonocytic leukaemia: A modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988;68:17-21.
2. Gonzalez-Medina I, Bueno J, Torrequebrada A, et al. Two groups of chronic myelomonocytic leukaemia: Myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res 2002;26:821-824.
3. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood 2002;99:840-849.
4. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004;45:1311-1318.
5. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96:375-383.
6. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013;121:3005-3015.
7. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
8. Beran M, Wen S, Shen Y, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007;48:1150-1160.
9. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88:967-974.
10. Patnaik MM, Padron E, Laborde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013;27:1504-1510.
11. Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two center study of 466 patients. Leukemia 2014; Apr 3 [Epub ahead of print].
12. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-3865.
13. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007;110:4385-4395.
14. Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000;108:346-356.
15. Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005;90:1168-1178.
16. Bacher U, Haferlach T, Kern W, et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 2005;84:250-257.
17. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.
18. Swerdlow SH, Campo C, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
19. Shaffer LG, McGowan-Jordan J, Schmid M. An international system for human cytogenetic nomenclature. Basel: S. Karger; 2013.
20. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-829.
21. Hussein K, Pardanani AD, Van Dyke DL, et al. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010;115:496-499.
22. Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1, 029 patients with primary myelodysplastic syndromes: A report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008;113:3331-3340.
23. Paulsson K, Heidenblad M, Strombeck B, et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 2006;20:840-846.